33 Firmen mit Ergebnissen für "acquired"

Bio-Technopark Schlieren-Zürich

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.

Bio-Technopark Schlieren-Zürich

Wagistrasse 23

8952 Schlieren

11 Ergebnisse für "acquired" unter Bio-Technopark Schlieren-Zürich

Proteomedix acquired by Blue Water Biotech to form Onconetix Inc., ...

... News Proteomedix acquired by Blue Water Biotech to form Onconetix Inc., a commercial stage men’s ... announced it has been acquired by US-based, NASDAQ-listed Blue Water Biotech Inc. (NASDAQ: BWV) in a share ... Proteomedix acquired by Blue Water Biotech to form Onconetix Inc., a commercial stage men’s health ... https://www.bio-technopark.ch/en/news-en/proteomedix- acquired-by-blue-water-biotech-to-form ... Proteomedix acquired by Blue Water Biotech to form Onconetix Inc., a commercial stage men’s health ...

... in Seoul, has launched a project to improve disease management in systemic... Proteomedix acquired by ... it has been acquired by US-based, NASDAQ-listed Blue Water Biotech Inc. (NASDAQ: BWV) in a share ...

Mehr Ergebnisse

Somagenetix

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

Somagenetix

Wagistrasse 23

8952 Schlieren

885 Ergebnisse für "acquired" unter Somagenetix

Idiopathic non-histaminergic acquired angioedema: a case series and...

... Copy Abstract BACKGROUND: Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare ... . Retrospectively registered 24.11.2016. Abstract BACKGROUND: Idiopathic non-histaminergic acquired angioedema ... Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published ... Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published ... Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published ...

Structural aspects of molecular recognition in the immune system. P...

... immune system. Part I: Acquired immunity (IUPAC Technical Report). Pure and Applied Chemistry, 86(10 ... Structural aspects of molecular recognition in the immune system. Part I: Acquired immunity (IUPAC ... Structural aspects of molecular recognition in the immune system. Part I: Acquired immunity (IUPAC ... Structural aspects of molecular recognition in the immune system. Part I: Acquired immunity (IUPAC ...

Mehr Ergebnisse

Molecular Partners AG

http://www.molecularpartners.com  

8952 Schlieren, Wagistrasse 14

 +41 44 755 77 00

Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.

Molecular Partners AG

Wagistrasse 14

8952 Schlieren

13 Ergebnisse für "acquired" unter Molecular Partners AG

BVF Partners L.P., a US-based investor focused on biotechnology inv...

... -investments- acquired-shares-from-pre-ipo-venture-capital-shareholders/ ... BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired shares from ... BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired shares from ...

Comments on: BVF Partners L.P., a US-based investor focused on biot...

... Comments on: BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired ... focused on biotechnology investments, acquired shares from pre-IPO venture capital shareholders Building ... Comments on: BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired ... -investments- acquired-shares-from-pre-ipo-venture-capital-shareholders/feed/ ... Comments on: BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired ...

Mehr Ergebnisse

University of Zurich

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

University of Zurich

Wagistrasse 12

8952 Schlieren

1262 Ergebnisse für "acquired" unter University of Zurich

Evaluation of spectrodirectional alfalfa canopy data acquired durin...

... Evaluation of spectrodirectional alfalfa canopy data acquired during DAISEX'99 - Geoscience and ... . 5, MAY 2003 Evaluation of Spectrodirectional Alfalfa Canopy Data Acquired During DAISEX’99 Gabriela ... Evaluation of spectrodirectional alfalfa canopy data acquired during DAISEX'99 - Geoscience and ... Evaluation of spectrodirectional alfalfa canopy data acquired during DAISEX'99 - Geoscience and ... Evaluation of spectrodirectional alfalfa canopy data acquired during DAISEX'99 - Geoscience and ...

First report of naturally acquired clinical sarcocystosis in a pig ...

... First report of naturally acquired clinical sarcocystosis in a pig breeding stock Copy Abstract A ... First report of naturally acquired clinical sarcocystosis in a pig breeding stock - Zurich Open ... First report of naturally acquired clinical sarcocystosis in a pig breeding stock - Zurich Open ... First report of naturally acquired clinical sarcocystosis in a pig breeding stock - Zurich Open ...

Mehr Ergebnisse

Roche Glycart AG

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

Roche Glycart AG

Wagistrasse 10

8952 Schlieren

101 Ergebnisse für "acquired" unter Roche Glycart AG

Roche | Roche Venture Fund Portfolio

... Ambrx ( acquired by Wuxi) Artus ( acquired by Qiagen) Avexis ( acquired by Novartis) BioFire ( acquired ... by bioMérieux) BioXell ( acquired by Cosmo) CGI ( acquired by Gilead) DVS ( acquired by Fluidigm) Envoy ... Portfolio Vaxcyte Vivet Therapeutics Exits via M&A M&A Afferent ( acquired by Merck) Alios ( acquired by ... Johnson+Johnson) Ambit ( acquired by Daiichi Sankyo) Ambrx ( acquired by Wuxi) Artus ( acquired by Qiagen ...

Elecsys® Toxo IgG

... common infection caused by the protozoan Toxoplasma gondii (T. gondii).1 The infection is mainly acquired ... .1 The risk of transmitting the infection to the fetus increases if the infection is acquired later ... mainly acquired by ingestion of food or water contaminated by cat feces or by undercooked meat from ... acquired later in the pregnancy, but the risk of fetal damage is highest when the infection is acquired ...

Mehr Ergebnisse

ETH Entrepreneurship

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18


 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

ETH Entrepreneurship

Wagistrasse 18

8952 Schlieren

442 Ergebnisse für "acquired" unter ETH Entrepreneurship

Letters From a Stoic – Xenotheka

... From a Stoic   The power and wealth which Seneca the Younger (c.4 B.C. – A.D. 65) acquired as ... From a Stoic   The power and wealth which Seneca the Younger (c.4 B.C. – A.D. 65) acquired as ...

Stoic philosophy – Xenotheka

... Stoic   The power and wealth which Seneca the Younger (c.4 B.C. – A.D. 65) acquired as Nero’ ... Stoic   The power and wealth which Seneca the Younger (c.4 B.C. – A.D. 65) acquired as Nero’ ...

Mehr Ergebnisse

Neurimmune Therapeutics AG

http://www.neurimmune.com  

8952 Schlieren, Wagistrasse 18

 +41 44 755 46 46
 info@neurimmune.com

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.

Neurimmune Therapeutics AG

Wagistrasse 18

8952 Schlieren

16 Ergebnisse für "acquired" unter Neurimmune Therapeutics AG

Neurimmune - 03.02.2016: BIIB076 (anti-tau mAb) moving into pre-IND...

... target that is believed to play a central role in Alzheimer's disease. Biogen  acquired Neurimmune’s anti ... . Biogen  acquired Neurimmune’s anti-tau program NI-105 in 2010, together with its anti-alpha-synuclein ...

Neurimmune - 19.02.2017: BIIB076 Moves into Phase 1 for Alzheimer's...

... antibody targeting tau, was discovered by Neurimmune and acquired by Biogen in 2010. The clinical trial ... recombinant monoclonal antibody targeting tau, was discovered by Neurimmune and acquired by Biogen in 2010 ...

Mehr Ergebnisse

CSL Vifor

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor  

8952 Schlieren, Wagistrasse 25

 +41 58 851 80 00

Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.

CSL Vifor

Wagistrasse 25

8952 Schlieren

38 Ergebnisse für "acquired" unter CSL Vifor

CSL Annual Report 2023 – Page 123

... and paid $11,665m for 100% of CSL Vifor shares (includes shares acquired in the prior year ended 30 ... accounting in accordance with AASB 3 ‘Business Combinations’ and consequently the CSL Vifor assets acquired ... acquired in the prior year ended 30 June 2022). The Group delisted Vifor Pharma Ltd from the Swiss Stock ... consequently the CSL Vifor assets acquired, and liabilities assumed, have been recorded at fair value, with any ...

CSL Annual Report 2023 – Page 122

... expenditure excludes PPE and intangible assets acquired in connection with the acquisition of CSL Vifor (Note ... ) amortisation of acquired IP (commercialised) of which $181m is attributable to CSL Limited shareholders (2022 ... underlying results 9 Capital expenditure excludes PPE and intangible assets acquired in connection with the ... (2022: $2m) amortisation of acquired IP (commercialised) of which $181m is attributable to CSL Limited ...

Mehr Ergebnisse

University Hospital Zurich​, Research and Education Office

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

University Hospital Zurich​, Research and Education Office

Rämistrasse 100

8091 Zürich

104 Ergebnisse für "acquired" unter University Hospital Zurich​, Research and Education Office

Slide A III 11b

... acquired while the fetus is still in the womb. ... period. Multiple fractures are acquired while the fetus is still in the womb. ...

... optical properties of a tissue using the data acquired from our TR-NIROT system Pioneer. Keywords: NIROT ... processing data acquired using in-house designed system called Pioneer. Pioneer is a time-resolved near ...

Mehr Ergebnisse

Kuros Biosciences AG

https://kurosbio.com/  

8952 Schlieren, Wagistrasse 25

 +41 (0)44 733 4747

Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing.

Kuros Biosciences AG

Wagistrasse 25

8952 Schlieren

26 Ergebnisse für "acquired" unter Kuros Biosciences AG

Prof. Dr. Joost de Bruijn* - Kuros Biosciences

... acquired by Kuros Biosciences AG early 2017. Prior to this, he was involved with Progentix Orthobiology BV ... (founder & CEO) that was acquired by NuVasive Inc. (now Globus Medical, Inc.), Scinus Cell Expansion BV ... . Prof. Dr. de Bruijn was the founder and CEO of Xpand Biotechnology B.V. that was acquired by Kuros ... was acquired by NuVasive Inc. (now Globus Medical, Inc.), Scinus Cell Expansion BV (founder & CEO) and ...

Kuros BioSciences - Overview

... technology' which led to our biologics program. In early 2017 Kuros acquired Xpand Biotechnology, adding ... Kuros acquired Xpand Biotechnology, adding substantial expertise in the surface science of ... program. In early 2017 Kuros acquired Xpand Biotechnology, adding substantial expertise in the surface ... Kuros acquired Xpand Biotechnology, adding substantial expertise in the surface science of ...

Mehr Ergebnisse

Mehr Firmen

Nach oben